跳至主要内容
临床试验/TCTR20210801005
TCTR20210801005已完成1 期

AT 2 genotype-guided INH dosage for tuberculosis treatment to reduce antituberculosis drug-induced liver injury in Thai patients

Department of medical services, Ministry of Public Health of Thailand0 个研究点目标入组 10 人开始时间: 2021年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 90 Years(—)
性别
All

入选标准

  • 1. Age more than 18 years
  • 2. Newly diagnosed pulmonary tuberculosis
  • 3. Slow acetylator phenotype
  • 4. Provided written informed consent

排除标准

  • 1) liver cirrhosis child pugh C; 2) alcoholism or alcohol drinking 14 days before enrollment abnormal liver function test at baseline; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN); 3) herbal medicine used; 4)HIV infection; 5) Chronic kidney disease define as eGFR < 30; 6) severe tuberculosis with high risk of poor outcome e.g., acute respiratory failure; 7) any conditions that may contribute unfavorable outcome; 8) life-threatening condition such as sepsis, respiratory failure, congestive heart failure; 9) body weight < 35 Kg and > 80 Kg; 10) pregnant and lactating woman.

研究者

发起方
Department of medical services, Ministry of Public Health of Thailand

相似试验

AT 2 genotype guided INH dosage for tuberculosis... | 临床试验